share_log

藥明生物：翌日披露報表

WUXI BIO: Next Day Disclosure Return

HKEX ·  Sep 2 10:47

Summary by Moomoo AI

藥明生物技術有限公司於2024年9月2日提交了翌日披露報表，披露其股份變動情況。報告顯示，公司於2024年9月2日購回了5,480,000股普通股，購回價格介乎於HKD 10.82至HKD 10.98之間，總支付價格為HKD 59,811,610。此次購回股份佔已發行股份的0.1319%，並計劃將這些股份註銷。此外，公司於2024年6月11日亦有購回1,810,000股股份，但尚未註銷。藥明生物確認，所有股份購回均按照香港聯合交易所有限公司的規則進行，並已獲得董事會的正式授權。購回後，公司將進入一個月的暫止期，直至2024年10月2日。
藥明生物技術有限公司於2024年9月2日提交了翌日披露報表，披露其股份變動情況。報告顯示，公司於2024年9月2日購回了5,480,000股普通股，購回價格介乎於HKD 10.82至HKD 10.98之間，總支付價格為HKD 59,811,610。此次購回股份佔已發行股份的0.1319%，並計劃將這些股份註銷。此外，公司於2024年6月11日亦有購回1,810,000股股份，但尚未註銷。藥明生物確認，所有股份購回均按照香港聯合交易所有限公司的規則進行，並已獲得董事會的正式授權。購回後，公司將進入一個月的暫止期，直至2024年10月2日。
Wuxi Bio submitted its disclosure report on September 2, 2024, disclosing changes in its shareholding. The report indicates that on September 2, 2024, the company repurchased 5,480,000 ordinary shares at a price ranging between HKD 10.82 and HKD 10.98, with a total payment of HKD 59,811,610. This repurchase accounts for 0.1319% of the issued shares, and the company plans to cancel these shares. In addition, the company also repurchased 1,810,000 shares on June 11, 2024, but they have not been canceled yet. Wuxi Bio confirmed that all share repurchases were carried out in accordance with the rules of the Hong Kong Stock Exchange and had obtained formal authorization from the board of directors. After the repurchase, the company will enter a one-month suspension period until October 2, 2024.
Wuxi Bio submitted its disclosure report on September 2, 2024, disclosing changes in its shareholding. The report indicates that on September 2, 2024, the company repurchased 5,480,000 ordinary shares at a price ranging between HKD 10.82 and HKD 10.98, with a total payment of HKD 59,811,610. This repurchase accounts for 0.1319% of the issued shares, and the company plans to cancel these shares. In addition, the company also repurchased 1,810,000 shares on June 11, 2024, but they have not been canceled yet. Wuxi Bio confirmed that all share repurchases were carried out in accordance with the rules of the Hong Kong Stock Exchange and had obtained formal authorization from the board of directors. After the repurchase, the company will enter a one-month suspension period until October 2, 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated